Identification
NameEthiodized oil
Accession NumberDB00965  (APRD00960)
TypeSmall Molecule
GroupsApproved
Description

Ethiodized oil is used by injection as a radio-opaque contrast agent. It is composed of iodine combined with ethyl esters of fatty acids of poppyseed oil, primarily as ethyl monoiodostearate and ethyl diiodostearate. The precise structure is not known.

Structure
Thumb
Synonyms
EOE 13
External IDs Not Available
Product Ingredients Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
LipiodolInjection480 mg/mLIntra-arterial; Intralymphatic; IntrauterineGuerbet2014-03-21Not applicableUs
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
EthiodolNot Available
Brand mixturesNot Available
Categories
UNIIKZW0R0686Q
CAS number8008-53-5
WeightNot Available
Chemical FormulaNot Available
InChI KeyNot Available
InChINot Available
IUPAC NameNot Available
SMILESNot Available
Pharmacology
Indication

For use as a radio-opaque medium for hysterosalpingography and lymphography, and as an antineoplastic agent when part of the iodine is 131-I. It is also used in follow-up imaging for chemoembolization.

Structured Indications
Pharmacodynamics

There has been little detailed investigation of the metabolic fate of ethiodized oil in either man or animals. However, the fate of ethiodized oil following Iymphangiography in dogs has been reported. Koehler et al. employed I131-tagged ethiodol for lymphangiography in dogs and analyses of individual organs at various time intervals were done. The investigators reported an average of only 25% of the injected medium was retained in the lymphatics at the end of three days. An average of 50% was recovered from the lungs. They found the remainder of injected activity was fairly uniformly distributed throughout the body. Urinary excretion in the form of inorganic iodine was revealed as the chief mode of iodine loss from the system.

Mechanism of action

Ethiodized oil is selectively retained in tumor vessels for long periods, and is used for imaging organs such as liver, lung, stomach, and thyroid. Labeled with I-131 or other beta emitters (Y-90 or P-32), ethiodized oil can deliver a high internal radiation dose to certain tumors with minimal effect on healthy tissues.

Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of elimination

Urinary excretion in the form of inorganic iodine was revealed as the chief mode of iodine loss from the system.

Half lifeNot Available
ClearanceNot Available
Toxicity

Intravenous LD50 in dog is 1580mg/kg. Symptoms of overdose include dyspnea and change in clotting factors.

Affected organisms
  • Humans and other mammals
PathwaysNot Available
Pharmacogenomic Effects/ADRs Not Available
Interactions
Drug Interactions
DrugInteractionDrug group
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Ethiodized oil.Approved
AldesleukinThe risk of a hypersensitivity reaction to Ethiodized oil is increased when it is combined with Aldesleukin.Approved
BevacizumabBevacizumab may increase the cardiotoxic activities of Ethiodized oil.Approved, Investigational
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Ethiodized oil.Approved
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Ethiodized oil.Approved, Investigational
DeslanosideDeslanoside may decrease the cardiotoxic activities of Ethiodized oil.Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of Ethiodized oil.Approved
DigoxinDigoxin may decrease the cardiotoxic activities of Ethiodized oil.Approved
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Ethiodized oil.Approved, Investigational
MetforminThe risk or severity of adverse effects can be increased when Ethiodized oil is combined with Metformin.Approved
OleandrinAnvirzel may decrease the cardiotoxic activities of Ethiodized oil.Experimental
OuabainOuabain may decrease the cardiotoxic activities of Ethiodized oil.Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Ethiodized oil.Approved, Vet Approved
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Ethiodized oil.Approved, Investigational
Food InteractionsNot Available
References
Synthesis ReferenceNot Available
General References
  1. Nelson RC: Techniques for computed tomography of the liver. Radiol Clin North Am. 1991 Nov;29(6):1199-212. [PubMed:1947041 ]
  2. Hamm B, Wolf KJ: Contrast material for computed tomography and magnetic resonance imaging of the gastrointestinal tract. Curr Opin Radiol. 1991 Jun;3(3):474-82. [PubMed:1859783 ]
  3. Link [Link]
External Links
ATC CodesNot Available
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSDownload (12.2 KB)
Clinical Trials
Clinical Trials
PhaseStatusPurposeConditionsCount
1, 2RecruitingTreatmentAdvanced Hepatocellular Carcinoma / Recurrence Hepatocellular Carcinoma1
2CompletedPreventionHepatocellular,Carcinoma1
2Unknown StatusNot AvailableLiver Cancer1
2, 3Not Yet RecruitingTreatmentHepatocellular,Carcinoma1
2, 3Unknown StatusTreatmentHepatocellular,Carcinoma1
3CompletedTreatmentLiver Cancer1
3RecruitingDiagnosticPulmonary Lesion With Ground-glass-opacity1
3RecruitingTreatmentChild-Pugh Class A / Child-Pugh Class B / Recurrent Hepatocellular Carcinoma1
3RecruitingTreatmentHepatocellular,Carcinoma3
3RecruitingTreatmentHepatocellular,Carcinoma / Portal Vein Tumor Thrombus1
3TerminatedPreventionHepatocellular,Carcinoma / Liver Cirrhosis / Neoplasm Recurrence, Local / Neoplasms, Hepatic / Recurrences1
4Not Yet RecruitingTreatmentHepatocellular,Carcinoma / Neoplastic Cells, Circulating1
4RecruitingTreatmentMetastatic Colorectal Cancers1
Not AvailableCompletedTreatmentGastric Varices / Portal Hypertension1
Pharmacoeconomics
Manufacturers
  • Guerbet llc
PackagersNot Available
Dosage forms
FormRouteStrength
InjectionIntra-arterial; Intralymphatic; Intrauterine480 mg/mL
PricesNot Available
PatentsNot Available
Properties
StateLiquid
Experimental Properties
PropertyValueSource
boiling point (°C)125 °C (at 8mm Hg)Not Available
water solubilityInsolubleNot Available
Predicted PropertiesNot Available
Predicted ADMET featuresNot Available
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Taxonomy
ClassificationNot classified
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23